BioFluidica, founded in San Diego, is a biotechnology company focused on developing advanced diagnostic platforms for disease management. Their core mission is to revolutionize medical diagnostics through innovative liquid biopsy technologies that capture and isolate circulating tumor cells (CTCs) and other biomarkers. BioFluidica's flagship products include LiquidScan, which facilitates exosome and fetal cell isolation, and next-generation liquid biopsy solutions. The company primarily serves the healthcare market, aiming to provide more accurate and less invasive diagnostic options.

Notable figures associated with BioFluidica include its leadership team and board of directors, who bring extensive expertise in biotechnology and medical diagnostics. The company has secured significant grants and investments to advance its research and development efforts. Key achievements include the successful development and commercialization of their liquid biopsy technologies, which have the potential to significantly impact early disease detection and personalized medicine. BioFluidica's innovations are poised to enhance diagnostic accuracy and patient outcomes, making a substantial impact on the healthcare industry.